These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14531913)

  • 1. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
    Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV
    Br J Haematol; 2003 Oct; 123(2):305-8. PubMed ID: 14531913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
    Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
    Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.
    Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H
    Br J Haematol; 2001 Dec; 115(3):605-8. PubMed ID: 11736942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent studies on the thalidomide and its derivatives.
    Łączkowski KZ; Baranowska-Łączkowska A
    Future Med Chem; 2018 Sep; 10(18):2133-2136. PubMed ID: 30088422
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiogenesis in multiple myeloma.
    Rajkumar SV; Kyle RA
    Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
    Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
    Leukemia; 2004 Mar; 18(3):624-7. PubMed ID: 14749707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
    Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
    Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
    Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
    Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
    Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
    Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow angiogenesis in multiple myeloma: effect of therapy.
    Kumar S; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
    Br J Haematol; 2002 Dec; 119(3):665-71. PubMed ID: 12437642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.